A detailed history of Convergence Investment Partners, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Convergence Investment Partners, LLC holds 1,306 shares of VRTX stock, worth $641,050. This represents 0.21% of its overall portfolio holdings.

Number of Shares
1,306
Previous 1,158 12.78%
Holding current value
$641,050
Previous $471,000 15.92%
% of portfolio
0.21%
Previous 0.25%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 03, 2024

BUY
$407.69 - $446.08 $60,338 - $66,019
148 Added 12.78%
1,306 $546,000
Q4 2023

Feb 05, 2024

SELL
$343.0 - $410.68 $55,909 - $66,940
-163 Reduced 12.34%
1,158 $471,000
Q3 2023

Nov 02, 2023

BUY
$338.18 - $362.46 $180,249 - $193,191
533 Added 67.64%
1,321 $459,000
Q2 2023

Jul 26, 2023

SELL
$314.42 - $351.91 $222,923 - $249,504
-709 Reduced 47.36%
788 $277,000
Q1 2023

May 09, 2023

SELL
$283.23 - $323.1 $75,339 - $85,944
-266 Reduced 15.09%
1,497 $472,000
Q4 2022

Feb 03, 2023

SELL
$285.76 - $321.48 $1,428 - $1,607
-5 Reduced 0.28%
1,763 $509,000
Q3 2022

Nov 08, 2022

BUY
$273.83 - $305.53 $123,497 - $137,794
451 Added 34.24%
1,768 $512,000
Q2 2022

Aug 05, 2022

BUY
$234.96 - $292.55 $28,195 - $35,106
120 Added 10.03%
1,317 $371,000
Q1 2022

Apr 26, 2022

BUY
$221.42 - $260.97 $265,039 - $312,381
1,197 New
1,197 $312,000
Q1 2021

Apr 30, 2021

SELL
$207.02 - $241.31 $285,480 - $332,766
-1,379 Closed
0 $0
Q4 2020

Feb 05, 2021

BUY
$207.01 - $276.09 $285,466 - $380,728
1,379 New
1,379 $326,000
Q2 2018

Aug 07, 2018

SELL
$145.72 - $169.96 $2.17 Million - $2.54 Million
-14,920 Closed
0 $0
Q1 2018

May 14, 2018

BUY
$151.6 - $177.13 $231,493 - $270,477
1,527 Added 11.4%
14,920 $2.43 Million
Q4 2017

Jan 16, 2018

SELL
$137.28 - $155.55 $77,288 - $87,574
-563 Reduced 4.03%
13,393 $2.01 Million
Q3 2017

Nov 13, 2017

BUY
$148.13 - $162.24 $2.07 Million - $2.26 Million
13,956
13,956 $2.12 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $126B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Convergence Investment Partners, LLC Portfolio

Follow Convergence Investment Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Convergence Investment Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Convergence Investment Partners, LLC with notifications on news.